TLR4 and mucopolysaccharidosis type 3B: A possible intervention to address bone pathology and simultaneously test the hypothesis that bone manifestations of MPS IIIB are partially driven by TLR4 overactivation would be a simple small-molecule TLR4 or TLR pathway inhibitor.